About US
Contact us
-
Aspen closes in on Africa license for Johnson & Johnson's COVID-19 vaccineOne of Johnson & Johnson’s long-held pandemic manufacturing partners just made headway in its quest to license the company’s shot in Africa. Aspen Pharmacare on Tuesday inked a non-binding term s2021/11/24
-
Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variantAs the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against t2021/11/24
-
Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeezeOn the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi and Eli Lilly are taking a beati2021/11/22
-
Former Insys execs ordered to pay $48.3M in restitution in Subsys opioid trialInsys Therapeutics' former top brass owes a collective $48.3 million in restitution for its role in the U.S. opioid crisis, a federal court in Boston ruled this month. Insys founder John Kapoor will2021/11/22
-
Late to the party: Europe on the verge of approving Roche and Celltrion antibodies for COVIDNearly a full year after the U.S. gaveRegeneron’s antibody cocktail for COVID-19 patients emergency authorization, Europe is onthe verge of approving the monoclonal antibody duo. The European Medicin2021/11/16
-
AstraZeneca's star China business slows on Tagrisso price cut, but Alexion may come to the rescueChina has delivered enviable growth for AstraZeneca in the past. But in the third quarter, the country became the main drag on AZ’s performance, thanks to a price cut to the company’s top-selling dru2021/11/16
-
Johnson & Johnson scores 60-day stay in high-profile talc litigation: reportAs Johnson & Johnson faces tens of thousands of lawsuits alleging its talc products caused users to develop cancer, a bankruptcy judge has granted the company a temporary reprieve. U.2021/11/12
-
Merck inks yet another $1B-plus supply deal for COVID pill, this time with JapanMerck & Co.'s positive data for oral COVID-19 antiviral molnupiravir continue to pay off in a big way. Wednesday, just a day after unveiling a $1 billion sale order to the U.S., the company discl2021/11/12
-
Moderna, U.S. clash in patent dispute over origins of COVID-19 vaccine: reportThe public/private partnership between the U.S. government and Moderna to quickly develop a COVID-19 vaccine has been lauded as a feel-good success story—and a blueprint for future health crises. But2021/11/10
-
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meetingAfter an FDA cold shoulder, FibroGen and partner AstraZeneca still aim to pave a way to market for anemia therapy roxadustat—even if it means conducting another clinical trial. The two companies are2021/11/10